Myricetin suppresses p21-activated kinase 1 in human breast cancer MCF-7 cells through downstream signaling of the β-catenin pathway

Jiao,De; Zhang,Xue  Dong

doi:10.3892/or.2016.4777

Myricetin suppresses p21-activated kinase 1 in human breast cancer MCF-7 cells through downstream signaling of the β-catenin pathway

Authors:
- De Jiao
- Xue Dong Zhang
View Affiliations

Affiliations: Department of Breast and Thyroid Hernia Surgery, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China, Department of Pathology, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China
Published online on: April 28, 2016 https://doi.org/10.3892/or.2016.4777
Pages: 342-348

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a main active compound in the bark of waxberry (Myrica rubra), myricetin is a macrocyclic diarylheptanoid, and can trigger the apoptosis of HeLa and PC3 cells. The aim of the present study was to elucidate the anticancer effect of myricetin on human breast cancer MCF-7 cells and to explore the possible mechanisms of action. MCF-7 cells were treated with different concentrations of myricetin (0-80 µM) for 12, 24 and 48 h. In the present study, we found that myricetin suppressed the cell viability of the MCF-7 cells at least partly through the induction of apoptosis as determined by MTT assay and flow cytometry. Western blot analysis revealed that myricetin effectively suppressed the protein expression of p21-activated kinase 1 (PAK1), MEK and phosphorylated extracellular mitogen-activated protein kinase (ERK1/2). In addition, treatment of myricetin activated glycogen synthase kinase-3β (GSK3β) and Bax protein expression, and inhibited β-catenin/cyclin D1/proliferating cell nuclear antigen (PCNA)/survivin and promoted caspase-3 activity in the MCF-7 cells. These results demonstrated that myricetin suppressed the cell viability of human breast cancer MCF-7 cells through PAK1/MEK/ERK/GSK3β/β-catenin/cyclin D1/PCNA/survivin/Bax-caspase-3 signaling.

View Figures

View References

1	Kida K, Ishikawa T, Yamada A, Shimizu D, Tanabe M, Sasaki T, Ichikawa Y and Endo I: A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer. Eur J Surg Oncol. 41:566–570. 2015. View Article : Google Scholar : PubMed/NCBI
2	Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, et al: Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol. 31:2115–2122. 2013. View Article : Google Scholar : PubMed/NCBI
3	Tang LC, Wang BY, Sun S, Zhang J, Jia Z, Lu YH, Di GH, Shao ZM and Hu XC: Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients. BMC Cancer. 13:2322013. View Article : Google Scholar : PubMed/NCBI
4	Yoon JH, Mo JS, Ann EJ, Ahn JS, Jo EH, Lee HJ, Hong SH, Kim MY, Kim EG, Lee K, et al: NOTCH1 intracellular domain negatively regulates PAK1 signaling pathway through direct interaction. Biochim Biophys Acta. 1863:179–188. 2016. View Article : Google Scholar
5	Khare V, Dammann K, Asboth M, Krnjic A, Jambrich M and Gasche C: Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer. Inflamm Bowel Dis. 21:287–296. 2015. View Article : Google Scholar : PubMed/NCBI
6	Nie J, Sun C, Faruque O, Ye G, Li J, Liang Q, Chang Z, Yang W, Han X and Shi Y: Synapses of amphids defective (SAD-A) kinase promotes glucose-stimulated insulin secretion through activation of p21-activated kinase (PAK1) in pancreatic β-cells. J Biol Chem. 287:26435–26444. 2012. View Article : Google Scholar : PubMed/NCBI
7	Chow HY, Jubb AM, Koch JN, Jaffer ZM, Stepanova D, Campbell DA, Duron SG, O'Farrell M, Cai KQ, Klein-Szanto AJ, et al: p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res. 72:5966–5975. 2012. View Article : Google Scholar : PubMed/NCBI
8	Wang L, Tian H, Yuan J, Wu H, Wu J and Zhu X: CONSORT: Sam68 is directly regulated by miR-204 and promotes the self-renewal potential of breast cancer cells by activating the Wnt/beta-catenin signaling pathway. Medicine. 94:e22282015. View Article : Google Scholar : PubMed/NCBI
9	Dong Y, Cao B, Zhang M, Han W, Herman JG, Fuks F, Zhao Y and Guo M: Epigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth. Oncotarget. 6:22126–22138. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kim ME, Ha TK, Yoon JH and Lee JS: Myricetin induces cell death of human colon cancer cells via BAX/BCL2-dependent pathway. Anticancer Res. 34:701–706. 2014.PubMed/NCBI
11	Iyer SC, Gopal A and Halagowder D: Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma. Mol Cell Biochem. 407:223–237. 2015. View Article : Google Scholar : PubMed/NCBI
12	Masuda T, Miura Y, Inai M and Masuda A: Enhancing effect of a cysteinyl thiol on the antioxidant activity of flavonoids and identification of the antioxidative thiol adducts of myricetin. Biosci Biotechnol Biochem. 77:1753–1758. 2013. View Article : Google Scholar : PubMed/NCBI
13	Kang KA, Wang ZH, Zhang R, Piao MJ, Kim KC, Kang SS, Kim YW, Lee J, Park D and Hyun JW: Myricetin protects cells against oxidative stress-induced apoptosis via regulation of PI3K/Akt and MAPK signaling pathways. Int J Mol Sci. 11:4348–4360. 2010. View Article : Google Scholar : PubMed/NCBI
14	Arving C, Brandberg Y, Feldman I, Johansson B and Glimelius B: Cost-utility analysis of individual psychosocial support interventions for breast cancer patients in a randomized controlled study. Psychooncology. 23:251–258. 2014. View Article : Google Scholar
15	Zhang J, Wang L, Wang Z, Hu X, Wang B, Cao J, Lv F, Zhen C, Zhang S and Shao Z: A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer. Cancer Biol Ther. 16:225–232. 2015. View Article : Google Scholar : PubMed/NCBI
16	DeSantiago J, Bare DJ, Xiao L, Ke Y, Solaro RJ and Banach K: p21-Activated kinase1 (Pak1) is a negative regulator of NADPH-oxidase 2 in ventricular myocytes. J Mol Cell Cardiol. 67:77–85. 2014. View Article : Google Scholar : PubMed/NCBI
17	McDaniel AS, Allen JD, Park SJ, Jaffer ZM, Michels EG, Burgin SJ, Chen S, Bessler WK, Hofmann C, Ingram DA, et al: Pak1 regulates multiple c-kit mediated Ras-MAPK gain-in-function phenotypes in Nf1^+/− masT cells. Blood. 112:4646–4654. 2008. View Article : Google Scholar : PubMed/NCBI
18	Holm C, Rayala S, Jirström K, Stål O, Kumar R and Landberg G: Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst. 98:671–680. 2006. View Article : Google Scholar : PubMed/NCBI
19	Smith SD, Jaffer ZM, Chernoff J and Ridley AJ: PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamics. J Cell Sci. 121:3729–3736. 2008. View Article : Google Scholar : PubMed/NCBI
20	Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, et al: P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene. 34:3968–3976. 2015. View Article : Google Scholar
21	Tarkkonen K, Ruohola J and Härkönen P: Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells. Growth Factors. 28:256–267. 2010. View Article : Google Scholar : PubMed/NCBI
22	Liu WH, Liu HB, Gao DK, Ge GQ, Zhang P, Sun SR, Wang HM and Liu SB: ABCG2 protects kidney side population cells from hypoxia/reoxygenation injury through activation of the MEK/ERK pathway. Cell Transplant. 22:1859–1868. 2013. View Article : Google Scholar
23	Navolanic PM, Lee JT and McCubrey JA: Docetaxel cytotoxicity is enhanced by inhibition of the Raf/MEK/ERK signal transduction pathway. Cancer Biol Ther. 2:677–678. 2003. View Article : Google Scholar : PubMed/NCBI
24	Li SQ, Wang ZH, Mi XG, Liu L and Tan Y: MiR-199a/b-3p suppresses migration and invasion of breast cancer cells by downregulating PAK4/MEK/ERK signaling pathway. IUBMB Life. 67:768–777. 2015. View Article : Google Scholar : PubMed/NCBI
25	Lim TG, Lee BK, Kwon JY, Jung SK and Lee KW: Acrylamide up-regulates cyclooxygenase-2 expression through the MEK/ERK signaling pathway in mouse epidermal cells. Food Chem Toxicol. 49:1249–1254. 2011. View Article : Google Scholar : PubMed/NCBI
26	Zhang J, Yang Z, Li P, Bledsoe G, Chao L and Chao J: Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol Cell Biochem. 379:295–301. 2013. View Article : Google Scholar : PubMed/NCBI
27	Chow KH, Sun RW, Lam JB, Li CK, Xu A, Ma DL, Abagyan R, Wang Y and Che CM: A gold(III) porphyrin complex with antitumor properties targets the Wnt/beta-catenin pathway. Cancer Res. 70:329–337. 2010. View Article : Google Scholar
28	Prasad CP, Chaurasiya SK, Axelsson L and Andersson T: WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells. Mol Oncol. 7:870–883. 2013. View Article : Google Scholar : PubMed/NCBI
29	Zhu L, Zhu B, Yang L, Zhao X, Jiang H and Ma F: RelB regulates Bcl-xl expression and the irradiation-induced apoptosis of murine prostate cancer cells. Biomed Rep. 2:354–358. 2014.PubMed/NCBI
30	Guo Y, Zhang Y, Yang X, Lu P, Yan X, Xiao F, Zhou H, Wen C, Shi M, Lu J, et al: Effects of methylglyoxal and glyoxalase I inhibition on breast Cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2. Cancer Biol Ther. 1–12. 2015.